Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IRIX 
IRIDEX Corporation (IRIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: IRIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.22% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.77M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) - | Beta 0.61 | 52 Weeks Range 0.78 - 2.41 | Updated Date 06/29/2025 |
52 Weeks Range 0.78 - 2.41 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Earnings Date
Report Date 2025-06-18 | When After Market | Estimate -0.12 | Actual -0.1008 |
Profitability
Profit Margin -14.61% | Operating Margin (TTM) -1.72% |
Management Effectiveness
Return on Assets (TTM) -9.54% | Return on Equity (TTM) -106.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12829343 | Price to Sales(TTM) 0.3 |
Enterprise Value 12829343 | Price to Sales(TTM) 0.3 | ||
Enterprise Value to Revenue 0.26 | Enterprise Value to EBITDA -3.61 | Shares Outstanding 16789000 | Shares Floating 11118197 |
Shares Outstanding 16789000 | Shares Floating 11118197 | ||
Percent Insiders 27.93 | Percent Institutions 18.76 |
Analyst Ratings
Rating - | Target Price 2 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
IRIDEX Corporation
Company Overview
History and Background
IRIDEX Corporation was founded in 1989. It is a worldwide leader in developing, manufacturing, and marketing innovative laser-based medical products for the treatment of glaucoma, retina, and other ophthalmic diseases.
Core Business Areas
- Retinal Disease: IRIDEX offers laser systems and single-use probes for treating retinal diseases like diabetic retinopathy and macular degeneration. These products include laser consoles and delivery devices for various retinal procedures.
- Glaucoma: Their glaucoma products include MicroPulse Transscleral Laser Therapy (MPTLT) lasers and devices for managing glaucoma by selectively targeting pigmented cells in the eye to lower intraocular pressure.
Leadership and Structure
Dominique Beckers is the President and Chief Executive Officer. The company has a Board of Directors that oversees strategic decisions and corporate governance.
Top Products and Market Share
Key Offerings
- Cyclo G6 Laser System: The Cyclo G6 laser system is used for MicroPulse TLT for glaucoma management. Competitors include companies offering alternative glaucoma treatments like medication and surgery. Revenue from this product contributes a significant portion of their revenue.
- Family of Laser Delivery Devices: These include a wide range of pattern scanning laser and fiber optic probes for use in retina and glaucoma therapies. Competitors include other companies offering laser delivery devices and those developing alternative treatment methods for retinal disease. Significant revenue contribution, precise revenue not available.
Market Dynamics
Industry Overview
The ophthalmic medical device industry is characterized by technological advancements in laser systems, increasing prevalence of eye diseases like glaucoma and diabetic retinopathy, and an aging global population driving demand. The market is competitive with many established players and innovative startups.
Positioning
IRIDEX is a established market player focused on laser-based solutions for glaucoma and retinal diseases. Their competitive advantage lies in MicroPulse technology and a comprehensive portfolio of laser systems and delivery devices. It holds a significant position as a leading supplier of ophthalmic laser systems.
Total Addressable Market (TAM)
The global ophthalmic devices market is expected to reach USD 61.5 billion by 2029. IRIDEX is positioned to capitalize on this TAM by expanding its offerings in glaucoma and retinal disease treatments and targeting emerging markets. No TAM is available for just ophthalmic lasers.
Upturn SWOT Analysis
Strengths
- Proprietary MicroPulse technology
- Established brand reputation in ophthalmic lasers
- Comprehensive product portfolio for glaucoma and retina
- Global sales and distribution network
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on laser-based technology; risk from alternative therapies
- Vulnerability to economic downturns affecting healthcare spending
- Limited range of product offering; competition from broader product ophthalmic manufacturers
Opportunities
- Expanding into emerging markets with growing healthcare infrastructure
- Developing new applications for MicroPulse technology
- Strategic partnerships and acquisitions to broaden product portfolio
- Increasing awareness of minimally invasive glaucoma surgery (MIGS) procedures
Threats
- Intense competition from established medical device companies
- Technological advancements leading to disruptive new therapies
- Changes in healthcare regulations and reimbursement policies
- Economic downturns affecting capital equipment spending
Competitors and Market Share
Key Competitors
- NVST
- LENS
- ALC
Competitive Landscape
IRIDEX competes with larger ophthalmic companies. IRIDEX's core strength is its innovation in laser technology. It can be disadvantaged by the breadth of it's products versus it's competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth needs to be calcultated using recent financial information.
Future Projections: Future Projections need to be calcultated using recent financial information and market analyst opinions.
Recent Initiatives: Recent Initiatives need to be calcultated using recent company information.
Summary
IRIDEX is an established company with innovative laser-based technology for treating eye diseases. The company's MicroPulse technology is a strength, but limited resources compared to competitors present challenges. To grow, IRIDEX should look to expand into emerging markets and build strategic partnerships. Economic factors impacting healthcare spending can have a significant effect on the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- IRIDEX Corporation website
- Company SEC filings
- Market research reports
- Analyst opinions
Disclaimers:
This analysis is based on publicly available information and represents an AI-driven interpretation. It is not financial advice. Market conditions and company performance may change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IRIDEX Corporation
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 1996-02-15 | CEO, President & Director Mr. Patrick Mercer | ||
Sector Healthcare | Industry Medical Devices | Full time employees 93 | Website https://www.iridex.com |
Full time employees 93 | Website https://www.iridex.com | ||
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.